Document is current
Any future updates will be listed below
-
Authors
Morin, Olivier https://orcid.org/0000-0002-9240-5704
Vallières, Martin https://orcid.org/0000-0001-7639-8172
Braunstein, Steve
Ginart, Jorge Barrios
Upadhaya, Taman
Woodruff, Henry C. https://orcid.org/0000-0001-7911-5123
Zwanenburg, Alex https://orcid.org/0000-0002-0342-9545
Chatterjee, Avishek
Villanueva-Meyer, Javier E.
Valdes, Gilmer
Chen, William
Hong, Julian C. https://orcid.org/0000-0001-5172-6889
Yom, Sue S. https://orcid.org/0000-0002-0779-7476
Solberg, Timothy D.
Löck, Steffen https://orcid.org/0000-0002-7017-3738
Seuntjens, Jan
Park, Catherine
Lambin, Philippe https://orcid.org/0000-0001-7961-0191
- License Information
-
More Information
Article History
Received: 14 April 2020
Accepted: 14 June 2021
First Online: 22 July 2021
Competing interests
: O.M. reports, within and outside the submitted work, grants/sponsored research agreements from Varian Medical. He received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind manpower contribution from Varian. O.M. has shares in the company Oncoradiomics. H.C.W. has shares in the company Oncoradiomics. J.E.V-M. reports funding from GE Healthcare, outside the scope of this submitted work. S.S.Y. reports grants/funding from Genentech, Merck, Bristol-Myers Squibb, BioMimetix and personal fees (UpToDate, Springer), outside the scope of this submitted work. J.S. is founding advisor of Gray Oncology Solutions Inc. and has commercialization projects of inventions unrelated to this work with the companies Lifeline Software Inc. and Sun Nuclear Corporation. P.L. reports, within and outside the submitted work, grants/sponsored research agreements from Radiomics SA, ptTheragnostic/DNAmito, Health Innovation Ventures. He received an advisor/presenter fee and/or reimbursement of travel costs/consultancy fee and/or in kind manpower contribution from Radiomics SA, BHV, Merck, Varian, Elekta, ptTheragnostic, BMS and Convert pharmaceuticals. P.L. has minority shares in the company Radiomics SA, Convert pharmaceuticals, Comunicare Solutions and LivingMed Biotech, and he is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Radiomics SA, one issued patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, one non-issued patent on LSRT (PCT/P126537PC00) licensed to Varian Medical, three non-patented invention (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures, and three non-issues, non-licensed patents on deep and handcrafted radiomics (US P125078US00, PCT/NL/2020/050794, number N2028271). He confirms that none of the above entities or funding was involved in the preparation of this paper.
